Europe Monoclonal Antibodies Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Monoclonal Antibodies Market Analysis

The Europe Monoclonal Antibodies Market is expected to register a CAGR of 9.47% during the forecast period.

The COVID-19 pandemic led to an urgent need for therapies to treat COVID-19 patients, and monoclonal antibodies emerged as a potential treatment option. During the initial phase of the pandemic, several monoclonal antibody treatments were developed and authorized for emergency use in Europe to help reduce the severity of the disease in certain patients. For instance, according to an article published by the Annals of Medicine Journal in October 2022, approximately four monoclonal antibody drugs regdanvimab (Regkirona), casirivimab/imdevimab (Ronapreve), sotrovimab (Xevudy), tixagevimab/cilgavimab (Evusheld) were approved by the European Union for the treatment of COVID-19 in Europe. Thus, approving monoclonal antibody drugs for COVID-19 treatment likely increased demand for these therapies in Europe. Therefore, looking at the overall scenario, the pandemic increased demand for monoclonal antibodies during the initial phase. However, as COVID-19 cases are declining in the region, the need for mAbs for severe COVID-19 treatment is expected to decrease. Thus, in the post-pandemic period, the market is expected to grow owing to factors other than COVID-19.

The major factors driving the growth of the Europe monoclonal antibodies market include the increasing burden of cancer and infectious diseases and the rising number of approvals of monoclonal antibodies.

The rising prevalence of solid tumor cases across European countries will drive market growth during the forecast period. Monoclonal antibodies have shown significant promise in the treatment of solid tumors, and they have become an essential component of targeted therapy by specifically targeting antigens present on the surface of cancer cells. By binding to these antigens, the antibodies block specific signaling pathways or deliver cytotoxic agents directly to the tumor cells, leading to their destruction. For instance, according to the October 2022 report of Macmillan Cancer Support, the incidence of cancer in the United Kingdom is increasing very rapidly, and it was estimated that the number of people living with cancer in the United Kingdom was projected to increase from 3.5 million in 2025 to 4 million by 2030. In addition, according to the data released by the Red Española de Registros de Cáncer (REDECAN) in January 2023, more than 279 thousand new cancer cases are expected to be reported in Spain in 2023. Also, the most frequent cancers diagnosed in men in Spain in 2023 are likely to be prostate (29,002), colon and rectum (26,357), and lung (22,266). Similarly, the most common cancer cases diagnosed in women are likely to be breast (35,001). Thus, a high prevalence of breast, colorectal, and lung cancer is projected to drive the demand for monoclonal antibodies like Trastuzumab (Herceptin) to treat HER2-positive breast cancer, Bevacizumab (Avastin) to treat advanced colorectal cancer and Nivolumab (Opdivo) and pembrolizumab (Keytruda) to treat lung cancer, thereby driving the overall market growth in the region.

In addition, monoclonal antibodies are used to treat various infectious diseases such as influenza, Respiratory Syncytial Virus (RSV), HIV, and rabies, among others. The region's high prevalence of these infectious diseases is projected to drive the overall market growth during the forecast period. For instance, according to the data released by the European Centre for Disease Prevention and Control (ECDC), as of February 2023, 231 thousand cases of influenza were reported across Europe. This represented a 5.2-fold increase in detections compared to the same period of the 2021-2022 season. Thus, a high prevalence of influenza cases is expected to drive the demand for monoclonal antibody therapeutics to target influenza hemagglutinin (HA), an envelope glycoprotein found on the influenza virion that allows the virus to enter and spread between cells.

Furthermore, the rising number of approvals of monoclonal antibodies by government agencies in the region for various therapeutic purposes is also likely to drive market growth during the forecast period. For instance, in November 2022, Sanofi and AstraZeneca received approval for its Beyfortus (nirsevimab) monoclonal antibody in the European Union (EU) indicated for respiratory syncytial virus (RSV) lower respiratory tract infections amongst infants and newborns. Thus, with the introduction of novel monoclonal antibodies in the region, the market for these therapeutic agents will likely expand during the forecast period. Moreover, the massive funding for research and development is also projected to drive market growth by accelerating innovations in mAbs in the region. For instance, in December 2022, SpikImm, a biotech company based in France, was awarded EUR 15 million (USD 16.6 million) from the French government for its "PROPHYMAB" project. The company is researching different monoclonal antibodies, including SPK001 and SPK002, for the prevention of COVID-19 "pre-exposure prophylaxis" in immunocompromised patients such as organ transplant patients, hematologic malignancies, autoimmune diseases, or certain HIV patients.

Therefore, due to the factors such as the increasing burden of cancer and infectious diseases and the rising number of approvals of monoclonal antibodies, the European monoclonal antibodies market is expected to register significant growth during the forecast period. However, the high cost of the method involved in producing monoclonal antibodies is expected to restrain market growth during the forecast period.